- $17.95m
- $7.80m
- $1.16m
- 25
- 26
- 19
- 12
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.02 | ||
| Price to Tang. Book | 1.1 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 5.94 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -182.91% | ||
| Return on Equity | -271.98% | ||
| Operating Margin | -1737.41% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.39 | 0.87 | n/a | n/a | 1.16 | 3.92 | 14.05 | -31.57% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received United States Food and Drug Administration (FDA) approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. It is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria (NTM) among others. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Its approved product and active pipeline of product candidates include LungFit PH, LungFit PRO and LungFit GO.
Directors
- Steven Lisi CHM (51)
- Amir Avniel PRE (48)
- Douglas Larson CFO (51)
- Andrew Colin OTH
- Ron Bentsur IND (56)
- Robert Carey IND (63)
- William Forbes IND (60)
- Yoori Lee IND (49)
- Erick Lucera IND (54)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 28th, 2015
- Public Since
- May 7th, 2019
- No. of Shareholders
- 105
- No. of Employees
- 107
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 88,278,647
- Address
- 900 STEWART AVENUE, SUITE 301, GARDEN CITY, 11530
- Web
- https://www.beyondair.net/
- Phone
- +1 5166658200
- Auditors
- Marcum LLP
Upcoming Events for XAIR
Q4 2025 Beyond Air Inc Earnings Release
Q1 2026 Beyond Air Inc Earnings Release
Similar to XAIR
Accelerate Diagnostics
NASDAQ Capital Market
Adagio Medical Holdings
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
What is the Beyond Air share price?
As of Today at 19:34 UTC, shares in Beyond Air are trading at $0.20. This share price information is delayed by 15 minutes.
How has the Beyond Air share price performed this year?
Shares in Beyond Air last closed at $0.20 and the price had moved by -83.34% over the past 365 days. In terms of relative price strength the Beyond Air share price has underperformed the S&P500 Index by -84.97% over the past year.
What are the analyst and broker recommendations for Beyond Air?
The overall consensus recommendation for Beyond Air is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Beyond Air dividend yield?
Beyond Air does not currently pay a dividend.
Does Beyond Air pay a dividend?
Beyond Air does not currently pay a dividend.
When does Beyond Air next pay dividends?
Beyond Air does not currently pay a dividend.
How do I buy Beyond Air shares?
To buy shares in Beyond Air you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Beyond Air?
As of the previous close price of $0.20, shares in Beyond Air had a market capitalisation of $17.95m.
Where are Beyond Air shares listed?
Here are the trading details for Beyond Air:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: XAIR
What kind of share is Beyond Air?
Based on an overall assessment of its quality, value and momentum Beyond Air is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Beyond Air share price forecast for 2025?
The analyst consensus target price for shares in Beyond Air is $2.25. That is 1006.74% above the last closing price of $0.20.
Analysts covering Beyond Air currently have a consensus Earnings Per Share (EPS) forecast of -$0.74 for the next financial year.
Find out moreWhat is the trend in the Beyond Air share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Beyond Air. Over the past six months, its share price has underperformed the S&P500 Index by -58.33%.
As of the last closing price of $0.20, shares in Beyond Air were trading -48.22% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Beyond Air PE Ratio?
The Beyond Air PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Beyond Air?
Beyond Air's management team is headed by:
- Steven Lisi - CHM
- Amir Avniel - PRE
- Douglas Larson - CFO
- Andrew Colin - OTH
- Ron Bentsur - IND
- Robert Carey - IND
- William Forbes - IND
- Yoori Lee - IND
- Erick Lucera - IND